Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano

Author:

Valenza Franco12,Papagni Gabriele1,Marchianò Alfonso3,Daidone Maria Grazia4,De’Braud Filippo25,Colombo Mario Paolo6,Frignani Andrea7,Galmozzi Gustavo8,Ladisa Vito9,Pruneri Giancarlo210,Salvioni Roberto11,Spada Pierangelo12,Torresani Michele13,Rinaldi Oliviero14,Manfredi Stefano15,Votta Marco16,Apolone Giovanni17

Affiliation:

1. Department of Anesthesia and Critical Care, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

2. Department of Oncology and Oncohematology, University of Milan, Milan, Italy

3. Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

4. Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

5. Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

6. Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

7. Managing Director, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

8. Medical Directorate, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

9. Pharmacy Unit, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

10. Department of Pathology and Laboratory Medicine University of Milan, School of Medicine, Milan, Italy

11. Urology Unit, Department of Surgery, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

12. Director, Nursing and Rehabilitation Management Service (SITRA), Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

13. Health Directorate, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

14. Chief Medical Officer, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

15. General Director, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

16. President, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

17. Scientific Director, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy

Abstract

Background: The rapid spread of coronavirus disease (COVID-19) is affecting many countries. While healthcare systems need to cope with the need to treat a large number of people with different degrees of respiratory failure, actions to preserve aliquots of the healthcare system to guarantee treatment to patients are mandatory. Methods: In order to protect the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano from the spread of COVID-19, a number of to-hospital and within-hospital filters were applied. Among others, a triage process to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity in patients with cancer was developed consisting of high-resolution low-dose computed tomography (CT) scan followed by reverse transcription polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in nose–throat swabs whenever CT was suggestive of lung infection. To serve symptomatic patients who were already admitted to the hospital or in need of hospitalization while waiting for RT-PCR laboratory confirmation of infection, a COVID-19 surveillance zone was set up. Results: A total of 301 patients were screened between March 6 and April 3, 2020. Of these, 47 were hospitalized, 53 needed a differential diagnosis to continue with their cancer treatment, and 201 were about to undergo surgery. RT-PCR was positive in 13 of 40 hospitalized patients (32%), 14 of 52 day hospital patients (27%), and 6 of 201 surgical patients (3%). Conclusion: Applying filters to protect our comprehensive cancer center from COVID-19 spread contributed to guaranteeing cancer care during the COVID-19 crisis in Milan. A surveillance area and surgical triage allowed us to protect the hospital from as many as 33 patients infected with SARS-CoV-2.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3